In addition, the use of the CD8/Treg frequency ratio as a marker is expected to correlate directly with cancer prognosis, irrespective of cancer type or stage, unlike a prognosis based on a the frequency of CD8+ cells or Tregs. This evidence concerns the gene CD8A and cancer.